X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs VENUS REMEDIES - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH VENUS REMEDIES STERLING BIOTECH/
VENUS REMEDIES
 
P/E (TTM) x -0.4 -4.4 - View Chart
P/BV x 0.0 0.2 8.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 STERLING BIOTECH   VENUS REMEDIES
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
VENUS REMEDIES
Mar-18
STERLING BIOTECH/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs11126 8.3%   
Low Rs361 5.6%   
Sales per share (Unadj.) Rs26.8301.8 8.9%  
Earnings per share (Unadj.) Rs-15.0-24.9 60.1%  
Cash flow per share (Unadj.) Rs-5.52.5 -214.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs54.9293.3 18.7%  
Shares outstanding (eoy) m267.8712.34 2,170.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 83.7%   
Avg P/E ratio x-0.5-3.8 12.4%  
P/CF ratio (eoy) x-1.336.7 -3.5%  
Price / Book Value ratio x0.10.3 39.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,8621,154 161.4%   
No. of employees `0001.40.9 146.4%   
Total wages/salary Rs m547393 139.1%   
Avg. sales/employee Rs Th5,303.34,026.1 131.7%   
Avg. wages/employee Rs Th403.8425.0 95.0%   
Avg. net profit/employee Rs Th-2,959.0-331.8 891.8%   
INCOME DATA
Net Sales Rs m7,1813,724 192.8%  
Other income Rs m4323 189.3%   
Total revenues Rs m7,2233,747 192.8%   
Gross profit Rs m947395 239.8%  
Depreciation Rs m2,543338 751.8%   
Interest Rs m4,377354 1,235.4%   
Profit before tax Rs m-5,931-275 2,154.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,92432 -6,089.6%   
Profit after tax Rs m-4,007-307 1,305.5%  
Gross profit margin %13.210.6 124.4%  
Effective tax rate %32.4-11.5 -282.7%   
Net profit margin %-55.8-8.2 677.1%  
BALANCE SHEET DATA
Current assets Rs m14,3352,638 543.5%   
Current liabilities Rs m49,8092,305 2,161.2%   
Net working cap to sales %-494.08.9 -5,524.4%  
Current ratio x0.31.1 25.1%  
Inventory Days Days403135 297.9%  
Debtors Days Days17146 368.3%  
Net fixed assets Rs m55,4324,871 1,138.1%   
Share capital Rs m268123 217.1%   
"Free" reserves Rs m13,9353,496 398.6%   
Net worth Rs m14,7013,619 406.2%   
Long term debt Rs m9,4781,374 689.6%   
Total assets Rs m73,9887,509 985.4%  
Interest coverage x-0.40.2 -159.2%   
Debt to equity ratio x0.60.4 169.8%  
Sales to assets ratio x0.10.5 19.6%   
Return on assets %0.50.6 79.3%  
Return on equity %-27.3-8.5 321.4%  
Return on capital %-6.41.6 -406.2%  
Exports to sales %25.90-   
Imports to sales %0.213.9 1.2%   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12517 2.4%   
Fx inflow Rs m1,8600-   
Fx outflow Rs m25517 4.8%   
Net fx Rs m1,835-517 -355.3%   
CASH FLOW
From Operations Rs m1,719514 334.1%  
From Investments Rs m-3,148-123 2,557.4%  
From Financial Activity Rs m1,426-387 -368.4%  
Net Cashflow Rs m-34 -81.0%  

Share Holding

Indian Promoters % 33.9 32.9 103.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.2 -  
FIIs % 9.9 0.6 1,706.9%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 66.4 59.2%  
Shareholders   21,482 20,121 106.8%  
Pledged promoter(s) holding % 55.9 36.4 153.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare STERLING BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

Tata Chem: Suspension of Haldia Operations Drag Bottomline Lower (Quarterly Results Update - Detailed)

Aug 17, 2017

Interruption at Haldia plant and fire at Lostock facility hits operations during the quarter.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Sep 17, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS